Scientific article

Syndrome hémolytique et urémique suite à un traitement de gemcitabine

Published inRevue médicale suisse, vol. 4, no. 154, p. 1056-1061
Publication date2008

Hemolytic uremic syndrome (HUS) in children is classically associated with diarrheas related to the production of a shiga-toxin. HUS occurs among oncologic patients, in relation with the cancer itself, or as a complication of the cytostatic treatment. The physician should be familiar with the triad of HUS (microangiopathic hemolytic anemia, thrombocytopenia and renal failure) and search actively for this pathology in oncologic patient. The treatment is essentially empirical. It includes plasma exchanges, control of blood pressure, hydro-electrolytic balance control with dialysis, if necessary. Blood transfusion should be avoided. Potential mortal complications associated with HUS can be prevented by a rapid diagnosis and a prompt initiation of adequate therapy.

  • Antimetabolites, Antineoplastic/adverse effects
  • Deoxycytidine/adverse effects/analogs & derivatives
  • Female
  • Hemolytic-Uremic Syndrome/chemically induced
  • Humans
  • Middle Aged
Citation (ISO format)
BOURQUIN, Vincent et al. Syndrome hémolytique et urémique suite à un traitement de gemcitabine. In: Revue médicale suisse, 2008, vol. 4, n° 154, p. 1056–1061.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation10/07/2014 2:59:00 PM
First validation10/07/2014 2:59:00 PM
Update time03/14/2023 9:49:48 PM
Status update03/14/2023 9:49:48 PM
Last indexation01/16/2024 12:01:48 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack